White Paper: Anatomy of a failure to launch: A review of barriers to generic and biosimilar market entry and the use of competition law as a remedy

Educational material on biosimilar medicines, developed by IGBA (International Generic and Biosimilar Medicines Association)

Positioning Statements on Physician-led Switching for Biosimilar Medicines

Positioning statements on physician-led switching for biosimilar medicines (September 2020)

Biosimilar medicines group position on physician-led switching (July 2015)

Biosimilar medicines group position on biologic pharmacy substitution (September 2020)

Job opportunities

No job opportunities are available at the moment.

Policy Roadmap for Medicines Manufacturing Leadership

Call for tenders SANTE/2020/C3/29 for the supply of medicinal products used for intensive care patients subject to the novel coronavirus (COVID-19) disease – policy and technical concerns

COVID-19 “Round 2” – Findings & way forward (Kearney)

Preparing for a potential second COVID-19 wave. Joint statement by Medicines for Europe and EFPIA with Kearney

LESSONS LEARNED FROM COVID-19 – POLICY PAPER

Quotes from 3rd VAM conference